GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (STU:35H) » Definitions » Short Percentage of Float

Homology Medicines (STU:35H) Short Percentage of Float


View and export this data going back to 2019. Start your Free Trial

What is Homology Medicines Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Homology Medicines's Short Percentage of Float

For the Biotechnology subindustry, Homology Medicines's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Homology Medicines's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Homology Medicines's Short Percentage of Float falls into.


Homology Medicines (STU:35H) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (STU:35H) » Definitions » Short Percentage of Float
Comparable Companies
ESLA OCUP OCEA CVM CLGN XLO HCWB GBIO CARA ADCT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
FIXX:USA
Address
One Patriots Park, Bedford, MA, USA, 01730
Website
https://www.homologymedicines.com
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (STU:35H) Headlines

No Headlines